Hasil Pencarian - Andrea Anichini

  • Menampilkan 1 - 15 hasil dari 15
Perbaiki Hasil
  1. 1
    The effect of artificial antigen-presenting cells with preclustered anti-CD28/-CD3/-LFA-1 monoclonal antibodies on the induction of ex vivo expansion of functional human antitumor T cells

    The effect of artificial antigen-presenting cells with preclustered anti-CD28/-CD3/-LFA-1 monoclonal antibodies on the induction of ex vivo expansion of functional human antitumor... oleh Roberta Zappasodi, Massimo Di Nicola, Carmelo Carlo-Stella, Roberta Mortarini, Alessandra Molla, Claudia Vegetti, Salvatore Albani, Andrea Anichini, Alessandro M. Gianni

    Diterbitkan 2008-10-01
    Dapatkan teks lengkap
    Artikel
    Simpan ke Daftar
    Disimpan di:
  2. 2
    A Bispecific Antibody to Link a TRAIL-Based Antitumor Approach to Immunotherapy

    A Bispecific Antibody to Link a TRAIL-Based Antitumor Approach to Immunotherapy oleh Alessandro Satta, Giulia Grazia, Francesco Caroli, Barbara Frigerio, Massimo Di Nicola, Francesco Raspagliesi, Delia Mezzanzanica, Nadia Zaffaroni, Alessandro Massimo Gianni, Andrea Anichini, Mariangela Figini

    Diterbitkan 2019-10-01
    Dapatkan teks lengkap
    Artikel
    Simpan ke Daftar
    Disimpan di:
  3. 3
    Growth-Inhibitory and Antiangiogenic Activity of the MEK Inhibitor PD0325901 in Malignant Melanoma with or without BRAF Mutations

    Growth-Inhibitory and Antiangiogenic Activity of the MEK Inhibitor PD0325901 in Malignant Melanoma with or without BRAF Mutations oleh Ludovica Ciuffreda, Donatella Del Bufalo, Marianna Desideri, Cristina Di Sanza, Antonella Stoppacciaro, Maria Rosaria Ricciardi, Sabina Chiaretti, Simona Tavolaro, Barbara Benassi, Alfonso Bellacosa, Robin Foà, Agostino Tafuri, Francesco Cognetti, Andrea Anichini, Gabriella Zupi, Michele Milella

    Diterbitkan 2009-08-01
    Dapatkan teks lengkap
    Artikel
    Simpan ke Daftar
    Disimpan di:
  4. 4
    Case Report: Exceptional Response to Avelumab After Failure of Electrochemotherapy in a Patient With Rapidly Progressive, PD-L1-Negative Merkel Cell Carcinoma

    Case Report: Exceptional Response to Avelumab After Failure of Electrochemotherapy in a Patient With Rapidly Progressive, PD-L1-Negative Merkel Cell Carcinoma oleh Martina Torchio, Laura Cattaneo, Massimo Milione, Natalie Prinzi, Francesca Corti, Marco Ungari, Andrea Anichini, Roberta Mortarini, Antonio Occhini, Giulia Bertino, Andrea Maurichi, Jorgelina Coppa, Maria Di Bartolomeo, Filippo Guglielmo de Braud, Filippo Guglielmo de Braud, Sara Pusceddu

    Diterbitkan 2021-06-01
    Dapatkan teks lengkap
    Artikel
    Simpan ke Daftar
    Disimpan di:
  5. 5
    Fifteen-year follow-up of relapsed indolent non-Hodgkin lymphoma patients vaccinated with tumor-loaded dendritic cells

    Fifteen-year follow-up of relapsed indolent non-Hodgkin lymphoma patients vaccinated with tumor-loaded dendritic cells oleh Filippo de Braud, Francesca De Santis, Roberta Zappasodi, Massimo Di Nicola, Margherita Ambrosini, Michele Magni, Luca Agnelli, Silvia Brich, Francesco Sgambelluri, Roberta Mortarini, Serenella M Pupa, Liliana Devizzi, Paola Matteucci, Antonello Cabras, Andrea Anichini, Alessandro M Gianni

    Diterbitkan 2021-06-01
    Dapatkan teks lengkap
    Artikel
    Simpan ke Daftar
    Disimpan di:
  6. 6
    Gut Microbiota, Metabolome, and Body Composition Signatures of Response to Therapy in Patients with Advanced Melanoma

    Gut Microbiota, Metabolome, and Body Composition Signatures of Response to Therapy in Patients with Advanced Melanoma oleh Giulia Vandoni, Federica D'Amico, Marco Fabbrini, Luigi Mariani, Sabina Sieri, Amanda Casirati, Lorenza Di Guardo, Michele Del Vecchio, Andrea Anichini, Roberta Mortarini, Francesco Sgambelluri, Giuseppe Celano, Nadia Serale, Maria De Angelis, Patrizia Brigidi, Cecilia Gavazzi, Silvia Turroni

    Diterbitkan 2023-07-01
    Dapatkan teks lengkap
    Artikel
    Simpan ke Daftar
    Disimpan di:
  7. 7
    Microenvironment and tumor inflammatory features improve prognostic prediction in gastro‐entero‐pancreatic neuroendocrine neoplasms

    Microenvironment and tumor inflammatory features improve prognostic prediction in gastro‐entero‐pancreatic neuroendocrine neoplasms oleh Massimo Milione, Rosalba Miceli, Francesco Barretta, Alessio Pellegrinelli, Paola Spaggiari, Giovanna Tagliabue, Giovanni Centonze, Cinzia Paolino, Alessandro Mangogna, Ketevani Kankava, Sara Pusceddu, Luca Giacomelli, Ambra Corti, Christian Cotsoglou, Vincenzo Mazzaferro, Gabriella Sozzi, Filippo deBraud, Giancarlo Pruneri, Andrea Anichini

    Diterbitkan 2019-10-01
    Dapatkan teks lengkap
    Artikel
    Simpan ke Daftar
    Disimpan di:
  8. 8
    A novel microRNA signature for the detection of melanoma by liquid biopsy

    A novel microRNA signature for the detection of melanoma by liquid biopsy oleh Claudia Sabato, Teresa Maria Rosaria Noviello, Alessia Covre, Sandra Coral, Francesca Pia Caruso, Zein Mersini Besharat, Elena Splendiani, Laura Masuelli, Cecilia Battistelli, Alessandra Vacca, Giuseppina Catanzaro, Agnese Po, Andrea Anichini, Michele Maio, Michele Ceccarelli, Anna Maria Di Giacomo, Elisabetta Ferretti

    Diterbitkan 2022-10-01
    Dapatkan teks lengkap
    Artikel
    Simpan ke Daftar
    Disimpan di:
  9. 9
    Semaphorin 5A drives melanoma progression: role of Bcl-2, miR-204 and c-Myb

    Semaphorin 5A drives melanoma progression: role of Bcl-2, miR-204 and c-Myb oleh Simona D’Aguanno, Elisabetta Valentini, Maria Grazia Tupone, Marianna Desideri, Marta Di Martile, Manuela Spagnuolo, Simonetta Buglioni, Cristiana Ercolani, Italia Falcone, Marco De Dominici, Michele Milella, Maria Giulia Rizzo, Bruno Calabretta, Carlo Cota, Andrea Anichini, Daniela Trisciuoglio, Donatella Del Bufalo

    Diterbitkan 2018-11-01
    Dapatkan teks lengkap
    Artikel
    Simpan ke Daftar
    Disimpan di:
  10. 10
    Epigenetic remodeling to improve the efficacy of immunotherapy in human glioblastoma: pre-clinical evidence for development of new immunotherapy approaches

    Epigenetic remodeling to improve the efficacy of immunotherapy in human glioblastoma: pre-clinical evidence for development of new immunotherapy approaches oleh Maria Fortunata Lofiego, Francesca Piazzini, Francesca Pia Caruso, Francesco Marzani, Laura Solmonese, Emma Bello, Fabrizio Celesti, Maria Claudia Costa, Teresa Noviello, Roberta Mortarini, Andrea Anichini, Michele Ceccarelli, Sandra Coral, Anna Maria Di Giacomo, Michele Maio, Alessia Covre, The EPigenetic Immune-oncology Consortium Airc (EPICA) investigators

    Diterbitkan 2024-03-01
    Dapatkan teks lengkap
    Artikel
    Simpan ke Daftar
    Disimpan di:
  11. 11
    Guadecitabine plus ipilimumab in unresectable melanoma: five-year follow-up and integrated multi-omic analysis in the phase 1b NIBIT-M4 trial

    Guadecitabine plus ipilimumab in unresectable melanoma: five-year follow-up and integrated multi-omic analysis in the phase 1b NIBIT-M4 trial oleh Teresa Maria Rosaria Noviello, Anna Maria Di Giacomo, Francesca Pia Caruso, Alessia Covre, Roberta Mortarini, Giovanni Scala, Maria Claudia Costa, Sandra Coral, Wolf H. Fridman, Catherine Sautès-Fridman, Silvia Brich, Giancarlo Pruneri, Elena Simonetti, Maria Fortunata Lofiego, Rossella Tufano, Davide Bedognetti, Andrea Anichini, Michele Maio, Michele Ceccarelli

    Diterbitkan 2023-09-01
    Dapatkan teks lengkap
    Artikel
    Simpan ke Daftar
    Disimpan di:
  12. 12
    IL-15, TIM-3 and NK cells subsets predict responsiveness to anti-CTLA-4 treatment in melanoma patients

    IL-15, TIM-3 and NK cells subsets predict responsiveness to anti-CTLA-4 treatment in melanoma patients oleh Rossana Tallerico, Costanza M. Cristiani, Elina Staaf, Cinzia Garofalo, Rosa Sottile, Mariaelena Capone, Yago Pico de Coaña, Gabriele Madonna, Eleonora Palella, Maria Wolodarski, Valentina Carannante, Domenico Mallardo, Ester Simeone, Antonio M. Grimaldi, Sofia Johansson, Paolo Frumento, Elio Gulletta, Andrea Anichini, Francesco Colucci, Gennaro Ciliberto, Rolf Kiessling, Klas Kärre, Paolo A. Ascierto, Ennio Carbone

    Diterbitkan 2017-02-01
    Dapatkan teks lengkap
    Artikel
    Simpan ke Daftar
    Disimpan di:
  13. 13
    Landscape of immune-related signatures induced by targeting of different epigenetic regulators in melanoma: implications for immunotherapy

    Landscape of immune-related signatures induced by targeting of different epigenetic regulators in melanoma: implications for immunotherapy oleh Andrea Anichini, Alessandra Molla, Gabriella Nicolini, Valentina Eleonora Perotti, Francesco Sgambelluri, Alessia Covre, Carolina Fazio, Maria Fortunata Lofiego, Anna Maria Di Giacomo, Sandra Coral, Antonella Manca, Maria Cristina Sini, Marina Pisano, Teresa Noviello, Francesca Caruso, Silvia Brich, Giancarlo Pruneri, Andrea Maurichi, Mario Santinami, Michele Ceccarelli, Giuseppe Palmieri, Michele Maio, Roberta Mortarini, On behalf of the EPigenetic Immune-oncology Consortium AIRC (EPICA) investigators

    Diterbitkan 2022-11-01
    Dapatkan teks lengkap
    Artikel
    Simpan ke Daftar
    Disimpan di:
  14. 14
    Antibody dependent cellular cytotoxicity-inducing anti-EGFR antibodies as effective therapeutic option for cutaneous melanoma resistant to BRAF inhibitors

    Antibody dependent cellular cytotoxicity-inducing anti-EGFR antibodies as effective therapeutic option for cutaneous melanoma resistant to BRAF inhibitors oleh Elena Muraro, Barbara Montico, Benedict Lum, Francesca Colizzi, Giorgio Giurato, Giorgio Giurato, Annamaria Salvati, Annamaria Salvati, Annamaria Salvati, Roberto Guerrieri, Aurora Rizzo, Elisa Comaro, Vincenzo Canzonieri, Vincenzo Canzonieri, Andrea Anichini, Michele Del Vecchio, Roberta Mortarini, Massimo Milione, Alessandro Weisz, Alessandro Weisz, Alessandro Weisz, Maria Antonietta Pizzichetta, Maria Antonietta Pizzichetta, Fiona Simpson, Riccardo Dolcetti, Riccardo Dolcetti, Riccardo Dolcetti, Riccardo Dolcetti, Elisabetta Fratta, Luca Sigalotti

    Diterbitkan 2024-03-01
    Dapatkan teks lengkap
    Artikel
    Simpan ke Daftar
    Disimpan di:
  15. 15
    PEOPLE (NTC03447678), a phase II trial to test pembrolizumab as first-line treatment in patients with advanced NSCLC with PD-L1

    PEOPLE (NTC03447678), a phase II trial to test pembrolizumab as first-line treatment in patients with advanced NSCLC with PD-L1 oleh Filippo de Braud, Valter Torri, Giuseppe Lo Russo, Claudia Proto, Roberto Ferrara, Monica Ganzinelli, Marina Chiara Garassino, Giuseppe Viscardi, Giorgio Trinchieri, Mario Occhipinti, Rita Leporati, Marta Brambilla, Luca Agnelli, Silvia Brich, Francesco Sgambelluri, Roberta Mortarini, Andrea Anichini, Leonardo Provenzano, Daniele Lorenzini, Arsela Prelaj, James Dolezal, Teresa Beninato, Tiziana Triulzi, Alessandra Fabbri, Laura Mazzeo, Andrea Spagnoletti, Vanja Miskovic, Alessandra Laura Giulia Pedrocchi, Francesco Trovo', Sara Manglaviti, Claudia Giani, Paolo Ambrosini, Andrea Franza, John McCulloch, Tommaso Torelli, Giancarlo Pruneri

    Diterbitkan 2023-06-01
    Dapatkan teks lengkap
    Artikel
    Simpan ke Daftar
    Disimpan di:

Alat Pencarian: